To confirm these data the recent Phase III CAPItello 291 clinical trial (NCT04305496) which assessed the efficacy of the AKT-inhibitor capivasertib combined fulvestrant in patients with advanced ER+ breast cancer was also analysed8. This evidence concerns the gene AKT1 and breast carcinoma.